Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Gross Margin (2016 - 2025)

Vanda Pharmaceuticals' Gross Margin history spans 13 years, with the latest figure at 93.3% for Q4 2025.

  • On a quarterly basis, Gross Margin fell 183.0% to 93.3% in Q4 2025 year-over-year; TTM through Dec 2025 was 93.96%, a 34.0% decrease, with the full-year FY2025 number at 93.96%, down 34.0% from a year prior.
  • Gross Margin hit 93.3% in Q4 2025 for Vanda Pharmaceuticals, down from 94.75% in the prior quarter.
  • Over the last five years, Gross Margin for VNDA hit a ceiling of 95.13% in Q4 2024 and a floor of 90.3% in Q3 2021.
  • Historically, Gross Margin has averaged 92.29% across 5 years, with a median of 92.36% in 2023.
  • Biggest five-year swings in Gross Margin: skyrocketed 277bps in 2024 and later crashed -183bps in 2025.
  • Tracing VNDA's Gross Margin over 5 years: stood at 90.83% in 2021, then dropped by -1bps to 90.33% in 2022, then rose by 2bps to 92.36% in 2023, then increased by 3bps to 95.13% in 2024, then decreased by -2bps to 93.3% in 2025.
  • Business Quant data shows Gross Margin for VNDA at 93.3% in Q4 2025, 94.75% in Q3 2025, and 94.8% in Q2 2025.